↓ Skip to main content

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

Overview of attention for article published in JAMA: Journal of the American Medical Association, April 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 30,428)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
76 Dimensions

Readers on

mendeley
460 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
Published in
JAMA: Journal of the American Medical Association, April 2021
DOI 10.1001/jama.2021.3071
Pubmed ID
Authors

Eduardo López-Medina, Pío López, Isabel C. Hurtado, Diana M Dávalos, Oscar Ramirez, Ernesto Martínez, Jesus A. Díazgranados, José M. Oñate, Hector Chavarriaga, Sócrates Herrera, Beatriz Parra, Gerardo Libreros, Roberto Jaramillo, Ana C. Avendaño, Dilian F. Toro, Miyerlandi Torres, Maria C. Lesmes, Carlos A. Rios, Isabella Caicedo

Abstract

Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. To determine whether ivermectin is an efficacious treatment for mild COVID-19. Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020. Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200). Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected. Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group). Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes. ClinicalTrials.gov Identifier: NCT04405843.

Twitter Demographics

The data shown below were collected from the profiles of 15,150 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 460 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 460 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 72 16%
Researcher 46 10%
Other 43 9%
Student > Master 36 8%
Student > Doctoral Student 31 7%
Other 113 25%
Unknown 119 26%
Readers by discipline Count As %
Medicine and Dentistry 155 34%
Pharmacology, Toxicology and Pharmaceutical Science 28 6%
Biochemistry, Genetics and Molecular Biology 26 6%
Nursing and Health Professions 20 4%
Agricultural and Biological Sciences 14 3%
Other 73 16%
Unknown 144 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 12563. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2021.
All research outputs
#71
of 19,206,351 outputs
Outputs from JAMA: Journal of the American Medical Association
#3
of 30,428 outputs
Outputs of similar age
#8
of 310,006 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#1
of 361 outputs
Altmetric has tracked 19,206,351 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 30,428 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 68.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,006 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 361 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.